Treatment Patterns and Healthcare Resource Utilization among Patients with Advanced or Metastatic Soft Tissue Sarcoma in US Community Practices.
Journal
Sarcoma
ISSN: 1357-714X
Titre abrégé: Sarcoma
Pays: Egypt
ID NLM: 9709257
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
06
2019
accepted:
28
01
2020
entrez:
8
4
2020
pubmed:
8
4
2020
medline:
8
4
2020
Statut:
epublish
Résumé
This study was designed to describe demographic and clinical characteristics of patients diagnosed with advanced or metastatic soft tissue sarcoma (STS) and to examine treatment and healthcare resource utilization patterns of this patient population in a United States (US) community-based oncology practice setting over time. A retrospective observational study was conducted within the US Oncology Network (USON). Patients were eligible if they were diagnosed with advanced or metastatic STS and were treated at a USON site between 01 July 2015 and 31 August 2018. Demographic, clinical, and treatment characteristics were described for the overall study population. Comparisons between patients by time period (prior to and after October 2016) were evaluated using the Demographic and clinical characteristics of the eligible study cohort ( While demographic and clinical characteristics were similar, treatment patterns changed in 2016. Future research should evaluate the impact of changing drug approvals and clinical trial results on future treatment patterns.
Identifiants
pubmed: 32256184
doi: 10.1155/2020/1765319
pmc: PMC7068137
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1765319Informations de copyright
Copyright © 2020 Eric Nadler et al.
Déclaration de conflit d'intérêts
Dr. Nadler, Ms. Aguilar, Dr. Wentworth, Mr. Boyd, Dr. Amirian, and Dr. Wilson were employees of McKesson Life Sciences, which received research funding from Eli Lilly and Co for conducting this study. Dr. Hess, Mr. Barker, and Ms. French were employed by Eli Lilly and Co during the study.
Références
BMC Cancer. 2017 Feb 7;17(1):111
pubmed: 28173774
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Sarcoma. 2018 May 24;2018:5467057
pubmed: 29977133
Surg Clin North Am. 2016 Oct;96(5):1141-56
pubmed: 27542647
Curr Treat Options Oncol. 2019 Jan 24;20(1):6
pubmed: 30675651
Lancet Oncol. 2017 Oct;18(10):1297-1299
pubmed: 28882535
Oncologist. 2005 Nov-Dec;10(10):833-41
pubmed: 16314294
Lancet. 2016 Jul 30;388(10043):488-97
pubmed: 27291997
Cancer Discov. 2016 Dec;6(12):1297
pubmed: 27827816
BMC Cancer. 2015 Mar 25;15:175
pubmed: 25885530
Sarcoma. 2014;2014:145764
pubmed: 24683310
Lancet Oncol. 2017 Oct;18(10):1397-1410
pubmed: 28882536
Am Soc Clin Oncol Educ Book. 2018 May 23;38:925-938
pubmed: 30231352
Ther Adv Med Oncol. 2017 Aug;9(8):533-550
pubmed: 28794805
Ther Adv Med Oncol. 2017 Oct;9(10):637-659
pubmed: 28974986
Clin Sarcoma Res. 2017 Nov 9;7:18
pubmed: 29152166